aflibercept-ayyh (Pavblu) vs Surabgene lomparvovec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

aflibercept-ayyh (Pavblu)

Marketed by Amgen

Approved in Age-Related Macular Degenerationfusion protein
Reliable signal

NCT04270747 · Phase 3 · completed

This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.

Reported efficacy

Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)

Result source: NCT04270747

Surabgene lomparvovec

Developed by AbbVie and partners

Phase 3 in Age-Related Macular DegenerationAAV gene therapy
Weak signal

NCT04832724 · Phase 2 · completed

The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.

Next expected readout: December 2026 · NCT04704921 (registry estimate)

Reported efficacy

RGX-314 target protein concentration in aqueous humor (At Week 24): Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 (not_applicable)

Result source: NCT04832724

Results for Age-Related Macular Degeneration

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. aflibercept-ayyh (Pavblu): 4 of 4 rows · Surabgene lomparvovec: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricaflibercept-ayyh (Pavblu)Surabgene lomparvovec
Dropout rate
5.2%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
16.7%Cohort 1a
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
0%Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0%Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0%Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
8.3%Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
0.3%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Cohort 1a
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
—Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Serious AEs
—ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
8.1%Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.1%Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
33.3%Cohort 1a
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
33.3%Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
25%Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
33.3%Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
neovascular age-related macular degeneration 5.9%
conjunctival haemorrhage 1.5%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 1 more result
conjunctival haemorrhage 4.2%
neovascular age-related macular degeneration 2.1%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
a
intraocular inflammation 66.7%
retinal haemorrhage 66.7%
visual acuity reduced/impairment 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
conjunctival haemorrhage 50%
intraocular inflammation 50%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
conjunctival haemorrhage 66.7%
intraocular inflammation 50%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 100%
conjunctival haemorrhage 75%
retinal thickening 33.3%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
conjunctival haemorrhage 91.7%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 91.7%
eye irritation 33.3%
NCT03066258 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

aflibercept-ayyh (Pavblu)

BCVA Change Letters 6.4 vs 6.5 Aflibercept Letters @ 8wk
absolute change · Letters
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 8 more results
5 vs 5.4 Aflibercept Letters @ 4wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.5 vs 7.6 Aflibercept Letters @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.8 vs 7.5 Aflibercept Letters @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 7.1 Aflibercept Letters @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.1 vs 8.7 Aflibercept Letters @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.3 vs 8.1 Aflibercept Letters @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 8.7 Aflibercept Letters @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.6 vs 9.4 Aflibercept Letters @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintained Vision 95.6% (n=251) vs 97.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 10 Letters 29.4% (n=279) vs 32.7% (n=281) Aflibercept @ 8wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 24.3% (n=251) vs 29.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CNV Area Change Mm2 -4.962 vs -5.479 Aflibercept mm @ 8wk
absolute change · mm
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 3 more results
-4.089 vs -5.174 Aflibercept mm @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-4.323 vs -5.308 Aflibercept mm @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-6.276 vs -7.28 Aflibercept mm @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CST Change Microns -136.5 vs -143.1 Aflibercept m @ 4wk
absolute change · m
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
-145.9 vs -146.3 Aflibercept m @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-125.2 vs -127.3 Aflibercept m @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-130.8 vs -131.7 Aflibercept m @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-133.2 vs -134.1 Aflibercept m @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -135.6 Aflibercept m @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -141.1 Aflibercept m @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-157.1 vs -159.1 Aflibercept m @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

Surabgene lomparvovec

BCVA Change Letters -7.6 ETDRS letters @ 106wk
absolute change · ETDRS letters
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
1.2 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
14 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0.9 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-3.8 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
CRT Change Microns -88.6 m @ 106wk
absolute change · m
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
25.3 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-56.7 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-108.2 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Supplemental Injection Rate Annualized 10.3 per year @ 106wk
event rate · per year
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
9.3 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2.8 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
4.4 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
CNV Area Change Mm2 -0.4 mm @ 106wk
absolute change · mm
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
0 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-1.2 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-1.1 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-0.6 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aflibercept-ayyh (Pavblu)'s landscape · Surabgene lomparvovec's landscape